Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | RBP4 | P02753 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115550 | 0.92 | P2RY12 (0.49) | P2RY12PDGFRBPDGFRACHRM4TRPA1 | |
| SCHEMBL1457424 | 0.90 | TRPA1 (0.43) | P2RY12PDGFRBPDGFRARBP4TRPA1 | |
| SCHEMBL1457229 | 0.89 | TRPA1 (0.54) | P2RY12PDGFRBPDGFRACHRM4TRPA1 | |
| SCHEMBL5127608 | 0.88 | TRPV1 (0.54) | RBP4TRPA1TRPV1 | |
| SCHEMBL1457523 | 0.88 | P2RY12 (0.48) | P2RY12RBP4CHRM4TRPA1TRPV1 | |
| SCHEMBL5127551 | 0.84 | RBP4 (0.62) | P2RY12RBP4TRPA1TRPV1 | |
| SCHEMBL5125630 | 0.83 | CHRM4 (0.48) | RBP4CHRM4TRPA1TRPV1 | |
| SCHEMBL5128423 | 0.83 | CHRM4 (0.55) | P2RY12CHRM4TRPA1TRPV1KIT | |
| SCHEMBL5111760 | 0.83 | CHRM4 (0.47) | RBP4CHRM4TRPA1TRPV1 | |
| SCHEMBL1457138 | 0.83 | P2RY12 (0.41) | P2RY12CHRM4TRPA1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | claimed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | REN, PKD1, NR3C2 | P2RY12 967/4885PDGFRB 1195/4885PDGFRA 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.